DEA Cannabis Rescheduling Hearings Enter Opposition Phase
Federal rescheduling proceedings advance as government concludes testimony and opposition groups begin presenting their case against moving cannabis to Schedule III.
The DEA's historic cannabis rescheduling hearings reached a pivotal juncture this week as federal prosecutors concluded their testimony supporting the proposed move from Schedule I to Schedule III. The National Drug and Alcohol Screening Association (NDASA) now leads opposition testimony, marking the beginning of what could prove the most contentious phase of these proceedings.
The government's case focused heavily on the Health and Human Services Department's scientific review, which found cannabis has accepted medical use and lower abuse potential than Schedule I substances. Federal attorneys presented evidence from clinical trials and state medical programs to support reclassification. This testimony reinforces the Biden administration's commitment to the rescheduling timeline, despite political uncertainty surrounding the incoming Trump administration.
NDASA's opposition centers on workplace safety concerns and drug testing complications that Schedule III status would create. The association argues that rescheduling undermines employer drug policies and federal workplace safety standards. Their testimony could influence how the DEA weighs public health considerations against medical access arguments, particularly given the association's ties to federal contractors and transportation industries.
The hearings carry substantial implications for cannabis operators across all market segments. Multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) stand to benefit most from 280E tax relief that Schedule III status would provide. Industry analysts estimate rescheduling could improve operator margins by 15-40% depending on current effective tax rates.
The opposition phase timeline remains fluid, but the DEA must balance thorough review against mounting industry pressure for resolution. Cannabis stocks have shown increased volatility around hearing developments, with the sector's performance increasingly tied to rescheduling progress rather than individual company fundamentals. The administrative process continues regardless of political transitions, though implementation timing could shift based on the final ruling's scope and any subsequent legal challenges.